[177Lu]Lu-rhPSMA-10.1 by Blue Earth Therapeutics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

[177Lu]Lu-rhPSMA-10.1 overview

Lutetium (177Lu) rhPSMA-10.1 is under development for the treatment of metastatic castrate-resistant prostate cancer. The therapeutic candidate comprises prostate-specific membrane antigen ligand labelled with the lutetium-177 (177Lu) radionuclide and is administered through intravenous route in the form of solution.

Blue Earth Therapeutics overview

Blue Earth Therapeutics, a subsidiary of Bracco SpA, is a clinical stage radiopharmaceutical company dedicated to the advancement of targeted radiotherapeutics to treat patients who have prostrate cancer. BET is headquartered in Oxford, Oxfordshire, the UK.

For a complete picture of [177Lu]Lu-rhPSMA-10.1’s drug-specific PTSR and LoA scores, buy the report here.

Subscribe to our Newsletter

Get industry leading news, data and analysis delivered to your inbox

Subscribe

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.